Early US dermatologist’s views of Tremfya leave ground to be covered
From: The Pharma Letter Early US dermatologist’s views of Tremfya leave ground to be covered At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya’s (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate […]
Janssen’s Tremfya (guselkumab) Makes its Debut in the Psoriasis Market and Early Dermatologist Feedback Reveals that Distinction from Stelara and the IL-17 Inhibitors will be Key to Success
According to recent data released from Spherix Global Insights, early US dermatologist’s views of Tremfya leave ground to be covered Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya’s approval when aided. Furthermore, less than one in […]
Novartis’ Cosentyx and Eli Lilly’s Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically
While AbbVie’s Humira and Amgen’s Enbrel have borne the brunt of the IL-17 assault, Janssen’s Stelara has been buffered thus far. However, future projections indicate a flattening of the brand and further penetration of the IL-17 class, according to a new report by Spherix Global Insights Download Report Overview EXTON, Pa., June 21, 2017 /PRNewswire/ […]
Dupixent Delivers… and Sanofi-Regeneron Ushers in a New Era of Atopic Dermatitis (AD) Treatment
According to Spherix Global Insights, at just one month post-launch, nearly one-third of surveyed dermatologists (n=101) have prescribed Dupixent, although for some a burdensome reimbursement process is slowing the time from prescription to fulfillment. Download Report Overview EXTON, Pa., May 17, 2017 /PRNewswire/ — According to the latest RealTime Dynamix™: Atopic Dermatitis report, just one […]
Preference, Persistency and Positioning for Lilly’s Taltz in Psoriasis Highlight a Potential Challenge Ahead for Novartis’ Cosentyx in PsO and Psoriatic Arthritis
Spherix Global Insights has released the results of two independent surveys of dermatologists (n=100) and rheumatologists (n=100) about the evolving practice patterns in the management of psoriasis (PsO) and psoriatic arthritis (PsA). Download Report Overview: Psoriasis Download Report Overview: Psoriatic Arthritis CAMBRIDGE, MASSACHUSETTS (PRWEB) APRIL 17, 2017 Despite positive perceptions, and brand expansion from the […]
RealTime Dynamix™: Atopic Dermatitis US Q2
Atopic dermatitis, the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until […]
RealTime Dynamix™: Psoriasis US Q2
The Psoriasis market continues to grow, driven by a growing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with both Cosentyx (Novartis) and 2016 launched Taltz from Eli Lilly. Tracking the interplay of these two highly regarded treatments will be central to the 2017 […]
Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration
IL-17s stop Janssen’s Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming – according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ — Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and […]
Pre-launch Intentions for Sanofi-Regeneron’s Dupixent (dupilumab) Suggest Rapid Uptake in an Area of High Unmet Need
100% of surveyed dermatologists see a role for Dupixent in their practices with most anticipating quick adoption according to a recent independent study by Spherix Global Insight Download Report Overview March 29, 2017 – Cambridge, Massachusetts. The future treatment of atopic dermatitis got a whole lot brighter yesterday with the approval of Sanofi-Regeneron’s Dupixent, the […]
RealTime Dynamix™: Atopic Dermatitis US Q1
Atopic dermatitis, the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until […]